Boel, Judith AMDS Study Group Mild Cognitive Impairment in Parkinson's Diseasede Bie, Rob M ASchmand, Ben ADalrymple-Alford, John CMarras, ConnieAdler, Charles HGoldman, Jennifer GTröster, Alexander IBurn, David JLitvan, IreneGeurtsen, Gert J2026-01-132026-01-132022-04-290885-3185https://hdl.handle.net/2445/225369Background: The criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown. Methods: The MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD. Results: PD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C-statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II. Conclusion: MMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD-MCI.5 p.application/pdfengcc by (c) Boel, Judith A et al., 2022https://creativecommons.org/licenses/by/4.0/Malaltia de ParkinsonDemènciaDiagnòsticParkinson's diseaseDementiaDiagnosisinfo:eu-repo/semantics/article7253222026-01-13info:eu-repo/semantics/openAccess35582313